董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eli Hazum | 男 | Acting Chief Executive Officer and Chief Technology Officer and Director | 72 | 未披露 | 未持股 | 2020-09-02 |
| Ehud Geller | 男 | Acting Chief Financial Officer and Executive Chairman | 73 | 未披露 | 未持股 | 2020-09-02 |
| Efi Cohen Arazi | 男 | Director | 65 | 未披露 | 未持股 | 2020-09-02 |
| Assif Stoffman | 男 | Director | 47 | 未披露 | 未持股 | 2020-09-02 |
| Ellen S. Baron | 女 | External Director | 68 | 未披露 | 未持股 | 2020-09-02 |
| Augustine Lawlor | 男 | External Director | 66 | 未披露 | 未持股 | 2020-09-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eli Hazum | 男 | Acting Chief Executive Officer and Chief Technology Officer and Director | 72 | 未披露 | 未持股 | 2020-09-02 |
| David E. Weinstein | 男 | President and Chief Medical Officer | 62 | 未披露 | 未持股 | 2020-09-02 |
| Ehud Geller | 男 | Acting Chief Financial Officer and Executive Chairman | 73 | 未披露 | 未持股 | 2020-09-02 |
| Sigal Aviel | 男 | Chief Operating Officer | 56 | 未披露 | 未持股 | 2020-09-02 |
董事简历
中英对照 | 中文 | 英文- Eli Hazum
-
Eli Hazum自2012年起担任代理首席执行官，自2018年4月起担任首席技术官，自2019年12月起担任公司董事。从2011年到2019年11月，他担任我们的首席执行官。他自1995年起担任Medica Venture Partners的合伙人和CSO。在加入Medica之前，Hazum教授在葛兰素公司（Glaxo Inc.）工作了五年，担任受体研究和代谢疾病部门的负责人，并担任全球骨质疏松症新技术识别公司委员会的成员。Hazum先生在魏茨曼科学研究所（Weizmann Institute of Science）获得激素生物化学领域的博士学位，在特拉维夫大学（Tel Aviv University）获得化学学士学位和硕士学位，并在英国汉伯赛德大学（Humberside University）获得执行工商管理硕士学位。本次发行完成后，Hazum先生将把60%的时间用于公司。
Eli Hazum has served as Chief Executive Officer since October 2021. He has been a partner and Chief Security Officer of Medica Venture Partners since 1995. Prior to joining Medica, Prof. Hazum spent five years at Glaxo Inc. as Head of the Department of Receptor Research and Metabolic Diseases and as a member of the Corporate Committee for New Technology Identification in osteoporosis, worldwide. Mr. Hazum received his Ph.D. degree in the field of hormone biochemistry from the izmann Institute of Science, B.Sc and M.Sc degrees in Chemistry from Tel Aviv University and an executive MBA degree from Humberside University in the UK. - Eli Hazum自2012年起担任代理首席执行官，自2018年4月起担任首席技术官，自2019年12月起担任公司董事。从2011年到2019年11月，他担任我们的首席执行官。他自1995年起担任Medica Venture Partners的合伙人和CSO。在加入Medica之前，Hazum教授在葛兰素公司（Glaxo Inc.）工作了五年，担任受体研究和代谢疾病部门的负责人，并担任全球骨质疏松症新技术识别公司委员会的成员。Hazum先生在魏茨曼科学研究所（Weizmann Institute of Science）获得激素生物化学领域的博士学位，在特拉维夫大学（Tel Aviv University）获得化学学士学位和硕士学位，并在英国汉伯赛德大学（Humberside University）获得执行工商管理硕士学位。本次发行完成后，Hazum先生将把60%的时间用于公司。
- Eli Hazum has served as Chief Executive Officer since October 2021. He has been a partner and Chief Security Officer of Medica Venture Partners since 1995. Prior to joining Medica, Prof. Hazum spent five years at Glaxo Inc. as Head of the Department of Receptor Research and Metabolic Diseases and as a member of the Corporate Committee for New Technology Identification in osteoporosis, worldwide. Mr. Hazum received his Ph.D. degree in the field of hormone biochemistry from the izmann Institute of Science, B.Sc and M.Sc degrees in Chemistry from Tel Aviv University and an executive MBA degree from Humberside University in the UK.
- Ehud Geller
-
Ehud Geller自2008年11月以来一直担任我们的董事会主席，自2020年1月以来担任我们的代理首席财务官。1995年以来，他一直担任Medica Venture Partners公司的普通合伙人。1979年至1985年，Geller博士担任Teva Pharmaceutical Industries NYSE:TEVA的制药部门总裁和Teva Group的执行副总裁。在Teva，他领导收购Ikapharm Ltd.。他从1985年到1990年担任InterPharm Laboratories，Ltd.总裁和首席执行官。在这些年里，他还担任以色列制药制造商协会（Israeli Pharmaceutical Manufacturers Association）的负责人和特拉维夫证券交易所（TASE）的董事会成员。Geller博士拥有理学学士学位。化学工程学位，Columbia University/Drexel Institute工商管理硕士学位和费城Drexel Institute制药/化学工程博士学位。1995年以来，他一直担任Medica Venture Partners公司的普通合伙人。
Ehud Geller has served as the Chairman of Board of Directors since 2007. Since 1995, Dr. Geller has served as the General Partner of Medica Venture Partners. Beten 1979 and 1985, Dr. Geller was President of the Pharmaceutical Division of Teva Pharmaceutical Indtries Ltd. (NYSE:TEVA) and Executive VP of the Teva Group. At Teva, he led the acquisition of Ikapharm Ltd. He served as the President and Chief Executive Officer of Interpharm Laboratories, Ltd. from 1985 to 1990. During these years he also served as head of the Israeli Pharmaceutical Manufacturers Association and as a Board Member on the Tel Aviv Stock Exchange. Dr. Geller has a B.Sc. degree in Chemical Engineering, an MBA degree from Columbia University/Drexel Institute and a Ph.D. degree in Pharmaceutical/Chemical Engineering from Drexel Institute, Philadelphia. Since 1995, he has been the General Partner of Medica Venture Partners. Mr. Geller was selected to serve on the board of directors as Chairman due to his significant experience leading and growing companies in the pharmaceutical indtry and his significant leadership experience. His experience leading the Company's management and the depth of his knowledge of biness enable him to provide valuable leadership on complex biness matters that face on an ongoing basis. Dr. Geller will devote approximately 50% of his time to the Company, as an executive Chairman, upon completion of this offering as he also is currently employed by Medica Venture Partners. - Ehud Geller自2008年11月以来一直担任我们的董事会主席，自2020年1月以来担任我们的代理首席财务官。1995年以来，他一直担任Medica Venture Partners公司的普通合伙人。1979年至1985年，Geller博士担任Teva Pharmaceutical Industries NYSE:TEVA的制药部门总裁和Teva Group的执行副总裁。在Teva，他领导收购Ikapharm Ltd.。他从1985年到1990年担任InterPharm Laboratories，Ltd.总裁和首席执行官。在这些年里，他还担任以色列制药制造商协会（Israeli Pharmaceutical Manufacturers Association）的负责人和特拉维夫证券交易所（TASE）的董事会成员。Geller博士拥有理学学士学位。化学工程学位，Columbia University/Drexel Institute工商管理硕士学位和费城Drexel Institute制药/化学工程博士学位。1995年以来，他一直担任Medica Venture Partners公司的普通合伙人。
- Ehud Geller has served as the Chairman of Board of Directors since 2007. Since 1995, Dr. Geller has served as the General Partner of Medica Venture Partners. Beten 1979 and 1985, Dr. Geller was President of the Pharmaceutical Division of Teva Pharmaceutical Indtries Ltd. (NYSE:TEVA) and Executive VP of the Teva Group. At Teva, he led the acquisition of Ikapharm Ltd. He served as the President and Chief Executive Officer of Interpharm Laboratories, Ltd. from 1985 to 1990. During these years he also served as head of the Israeli Pharmaceutical Manufacturers Association and as a Board Member on the Tel Aviv Stock Exchange. Dr. Geller has a B.Sc. degree in Chemical Engineering, an MBA degree from Columbia University/Drexel Institute and a Ph.D. degree in Pharmaceutical/Chemical Engineering from Drexel Institute, Philadelphia. Since 1995, he has been the General Partner of Medica Venture Partners. Mr. Geller was selected to serve on the board of directors as Chairman due to his significant experience leading and growing companies in the pharmaceutical indtry and his significant leadership experience. His experience leading the Company's management and the depth of his knowledge of biness enable him to provide valuable leadership on complex biness matters that face on an ongoing basis. Dr. Geller will devote approximately 50% of his time to the Company, as an executive Chairman, upon completion of this offering as he also is currently employed by Medica Venture Partners.
- Efi Cohen Arazi
-
Efi Cohen Arazi自2008年以来是Rainbow Medical，Israel领先的医疗设备创新之家的联合创始人兼首席执行官。从2004年到2006年，Cohen Arazi先生担任IntecPharma Ltd.的首席执行官兼联合创始人，并自2006年以来担任Collplant Ltd.的董事长。Cohen Arazi先生自2005年以来担任众多生物技术/医疗技术公司的董事会董事。他曾担任Immunex Corporation（位于华盛顿西雅图）的高级运营副总裁，直到2002年公司被Amgen公司收购，在那里他曾担任the To Site（位于加州）的副总裁兼总经理。Cohen Arazi先生于1988年至2000年在瑞士和以色列的Merck-Serono Group任职。Cohen-Arazi先生以优异成绩毕业，获得理学硕士学位。the Hebrew University of Jerusalem，以色列学位。
Efi Cohen Arazi was the Co-Founder & CEO of Rainbow Medical, Israel’s leading medical device innovation house since 2008. From 2004 to 2006 Mr. Cohen Arazi served as the CEO and Co-Founder of IntecPharma Ltd. and as Chairman of CollPlant Ltd. since 2006. Mr. Cohen Arazi served as a board director for numerous biotech/medtech companies since 2005. Mr. Cohen-Arazi was the Senior VP Head of Operations at Immunex Corporation in Seattle, Washington until 2002 when it was acquired by Amgen where he served as VP and General Manager of the TO site in California. Mr. Cohen Arazi served at Merck-Serono Group in Switzerland and Israel between 1988 and 2000. Mr. Cohen-Arazi graduated summa cum laude with a M.Sc. degree from the Hebrew University of Jerusalem, Israel. - Efi Cohen Arazi自2008年以来是Rainbow Medical，Israel领先的医疗设备创新之家的联合创始人兼首席执行官。从2004年到2006年，Cohen Arazi先生担任IntecPharma Ltd.的首席执行官兼联合创始人，并自2006年以来担任Collplant Ltd.的董事长。Cohen Arazi先生自2005年以来担任众多生物技术/医疗技术公司的董事会董事。他曾担任Immunex Corporation（位于华盛顿西雅图）的高级运营副总裁，直到2002年公司被Amgen公司收购，在那里他曾担任the To Site（位于加州）的副总裁兼总经理。Cohen Arazi先生于1988年至2000年在瑞士和以色列的Merck-Serono Group任职。Cohen-Arazi先生以优异成绩毕业，获得理学硕士学位。the Hebrew University of Jerusalem，以色列学位。
- Efi Cohen Arazi was the Co-Founder & CEO of Rainbow Medical, Israel’s leading medical device innovation house since 2008. From 2004 to 2006 Mr. Cohen Arazi served as the CEO and Co-Founder of IntecPharma Ltd. and as Chairman of CollPlant Ltd. since 2006. Mr. Cohen Arazi served as a board director for numerous biotech/medtech companies since 2005. Mr. Cohen-Arazi was the Senior VP Head of Operations at Immunex Corporation in Seattle, Washington until 2002 when it was acquired by Amgen where he served as VP and General Manager of the TO site in California. Mr. Cohen Arazi served at Merck-Serono Group in Switzerland and Israel between 1988 and 2000. Mr. Cohen-Arazi graduated summa cum laude with a M.Sc. degree from the Hebrew University of Jerusalem, Israel.
- Assif Stoffman
-
Assif Stoffman自2020年1月起担任公司董事。自2020年1月起，斯托夫曼先生共同管理XT Hi-Tech，该公司是全球航运和工业集团XT Holdings的风险投资部门。在2012年至2018年6月期间，斯托夫曼先生是MValve Technologies Ltd的联合创始人兼首席执行官，开创了治疗二尖瓣疾病的革命性概念。在加入mValve之前，2009年至2012年，斯托夫曼先生担任XT Hi-Tech的执行Vice President，负责软件和梦百合投资。Stoffman先生是被Insight Venture Partners收购的Checkmarx的创始投资者和执行主席，并担任JetPrep（被Cantel Medical收购；NYSE:CMD），CMYCASA（被Adobe收购；NASDAQ:ADBE）和ActiViews（被Stryker收购；NYSE:SYK）的董事会成员。2004年至2008年，他曾担任Naiot Venture Accelerator公司（领先的梦百合和软件加速器）的首席执行官，在那里他曾领导众多初创公司的创立。Stoffman先生拥有法学硕士学位。Bar-Ilan University和LL.B.（谈判和争端解决）学位。以及Herzliya跨学科中心学士学位（工商管理）。
Assif Stoffman has served as a director of the company since January 2020. Since January 2020 Mr. Stoffman is co-managing XT Hi-Tech, the venture capital arm of the global shipping & industrial group XT Holdings. Between 2012 and June 2018 Mr. Stoffman was the co-founder and CEO of MValve Technologies Ltd, pioneering a revolutionary concept in treating mitral valve disease. Prior to MValve, between 2009 and 2012 Mr. Stoffman served as Executive Vice President of XT Hi-Tech, in charge of software and healthcare investments. Mr. Stoffman was the founding investor and executive chairman of Checkmarx acquired by Insight Venture Partners, and served on the board of directors of JetPrep (acquired by Cantel Medical; NYSE: CMD), CmyCasa (acquired by Adobe; NASDAQ: ADBE) and Activiews (acquired by Stryker; NYSE:SYK). Between 2004 and 2008 Mr. Stoffman was the CEO of Naiot Venture Accelerator, a leading healthcare and software accelerator, where he was leading the foundation of numerous start-up companies. Mr. Stoffman holds an LL.M. (negotiations and dispute resolution) degree from Bar-Ilan University and LL.B. and BA (Business Administration) degrees from the Interdisciplinary Center, Herzliya. - Assif Stoffman自2020年1月起担任公司董事。自2020年1月起，斯托夫曼先生共同管理XT Hi-Tech，该公司是全球航运和工业集团XT Holdings的风险投资部门。在2012年至2018年6月期间，斯托夫曼先生是MValve Technologies Ltd的联合创始人兼首席执行官，开创了治疗二尖瓣疾病的革命性概念。在加入mValve之前，2009年至2012年，斯托夫曼先生担任XT Hi-Tech的执行Vice President，负责软件和梦百合投资。Stoffman先生是被Insight Venture Partners收购的Checkmarx的创始投资者和执行主席，并担任JetPrep（被Cantel Medical收购；NYSE:CMD），CMYCASA（被Adobe收购；NASDAQ:ADBE）和ActiViews（被Stryker收购；NYSE:SYK）的董事会成员。2004年至2008年，他曾担任Naiot Venture Accelerator公司（领先的梦百合和软件加速器）的首席执行官，在那里他曾领导众多初创公司的创立。Stoffman先生拥有法学硕士学位。Bar-Ilan University和LL.B.（谈判和争端解决）学位。以及Herzliya跨学科中心学士学位（工商管理）。
- Assif Stoffman has served as a director of the company since January 2020. Since January 2020 Mr. Stoffman is co-managing XT Hi-Tech, the venture capital arm of the global shipping & industrial group XT Holdings. Between 2012 and June 2018 Mr. Stoffman was the co-founder and CEO of MValve Technologies Ltd, pioneering a revolutionary concept in treating mitral valve disease. Prior to MValve, between 2009 and 2012 Mr. Stoffman served as Executive Vice President of XT Hi-Tech, in charge of software and healthcare investments. Mr. Stoffman was the founding investor and executive chairman of Checkmarx acquired by Insight Venture Partners, and served on the board of directors of JetPrep (acquired by Cantel Medical; NYSE: CMD), CmyCasa (acquired by Adobe; NASDAQ: ADBE) and Activiews (acquired by Stryker; NYSE:SYK). Between 2004 and 2008 Mr. Stoffman was the CEO of Naiot Venture Accelerator, a leading healthcare and software accelerator, where he was leading the foundation of numerous start-up companies. Mr. Stoffman holds an LL.M. (negotiations and dispute resolution) degree from Bar-Ilan University and LL.B. and BA (Business Administration) degrees from the Interdisciplinary Center, Herzliya.
- Ellen S. Baron
-
本次发行完成后，Ellen S.Baron将加入公司董事会。Baron博士自2017年2月起担任专业生命科学和技术咨询及投资银行公司Outcome Capital LLC的管理合伙人。从2012年到加入Outcome Capital，她曾担任Healthios Capital Markets，LLC的董事总经理。在加入Healthios之前，Baron博士曾担任牛津生物科学合伙公司（Oxford Bioscience Partners）的生命科学风险投资合伙人，以及上市生物制药公司Human Genome Sciences的高级副总裁，业务开发。Baron博士此前曾在Schering-PloughCorporation工作了20年，从事研究与开发和业务开发。Baron博士目前担任Tetragenetics Inc.（一家生物技术公司）、Sixth Element Capital（一家总部位于英国的肿瘤专注风险投资基金）和SFH（一家总部位于缅因州的营养公司）的董事会成员。Baron博士拥有乔治敦大学医学院（Georgetown University School of Medicine）的微生物学博士学位，纽约公共卫生研究所（Public Health Research Institute）的博士后学位和Goucher College的学士学位。
Ellen S. Baron will join the Company’s board of directors upon the completion of this offering. Dr, Baron has been a managing partner of Outcome Capital LLC, a specialized life science and technology advisory and investment banking firm since February 2017. From 2012 until joining Outcome Capital, she served as a Managing Director of Healthios Capital Markets, LLC. Prior to joining Healthios, Dr. Baron served as a life science venture capital Partner for Oxford Bioscience Partners and as Senior Vice President, Business Development at Human Genome Sciences, a publicly traded biopharmaceutical company. Dr. Baron previously had spent 20 years at Schering-Plough Corporation in both Research and Development and Business Development. Dr. Baron currently serves on the Board of Directors of Tetragenetics Inc., a biotech company, Sixth Element Capital, a UK-based oncology focused venture capital fund and SFH, a Maine-based nutraceutical company. Dr. Baron holds a Ph.D. in Microbiology from Georgetown University School of Medicine, a post-doctorate at the Public Health Research Institute in New York and bachelor’s degree from Goucher College. - 本次发行完成后，Ellen S.Baron将加入公司董事会。Baron博士自2017年2月起担任专业生命科学和技术咨询及投资银行公司Outcome Capital LLC的管理合伙人。从2012年到加入Outcome Capital，她曾担任Healthios Capital Markets，LLC的董事总经理。在加入Healthios之前，Baron博士曾担任牛津生物科学合伙公司（Oxford Bioscience Partners）的生命科学风险投资合伙人，以及上市生物制药公司Human Genome Sciences的高级副总裁，业务开发。Baron博士此前曾在Schering-PloughCorporation工作了20年，从事研究与开发和业务开发。Baron博士目前担任Tetragenetics Inc.（一家生物技术公司）、Sixth Element Capital（一家总部位于英国的肿瘤专注风险投资基金）和SFH（一家总部位于缅因州的营养公司）的董事会成员。Baron博士拥有乔治敦大学医学院（Georgetown University School of Medicine）的微生物学博士学位，纽约公共卫生研究所（Public Health Research Institute）的博士后学位和Goucher College的学士学位。
- Ellen S. Baron will join the Company’s board of directors upon the completion of this offering. Dr, Baron has been a managing partner of Outcome Capital LLC, a specialized life science and technology advisory and investment banking firm since February 2017. From 2012 until joining Outcome Capital, she served as a Managing Director of Healthios Capital Markets, LLC. Prior to joining Healthios, Dr. Baron served as a life science venture capital Partner for Oxford Bioscience Partners and as Senior Vice President, Business Development at Human Genome Sciences, a publicly traded biopharmaceutical company. Dr. Baron previously had spent 20 years at Schering-Plough Corporation in both Research and Development and Business Development. Dr. Baron currently serves on the Board of Directors of Tetragenetics Inc., a biotech company, Sixth Element Capital, a UK-based oncology focused venture capital fund and SFH, a Maine-based nutraceutical company. Dr. Baron holds a Ph.D. in Microbiology from Georgetown University School of Medicine, a post-doctorate at the Public Health Research Institute in New York and bachelor’s degree from Goucher College.
- Augustine Lawlor
-
本次发行完成后，Augustine Lawlor将加入公司董事会。劳勒先生自2016年1月起担任肿瘤公司LeapTherapeutics，Inc.的首席运营官，并自2000年起担任梦百合Ventures的董事总经理。从1997年到2000年，他曾担任Leukosite公司（生物技术公司，于1999年被Millennium Pharmaceuticals公司收购）的首席运营官。在加入Leukosite之前，Lawlor先生是Alpha-Beta Technologies，Inc.（一家专门从事电子产品设计、开发、制造和系统过时问题的公司）企业发展的首席财务官和Vice President。他曾在Biosurface Technologies Corporation（一家为生物膜调查提供产品的公司）和Armstrong Pharmaceuticals（一家专业制药公司AmphastarPharmaceuticals，Inc.的子公司）担任类似职务。Lawlor先生此前是毕马威会计师事务所（KPMG）的管理顾问。他目前是在纳斯达克上市的生物制药公司CatalystBiosciences，Inc.的董事会主席和CardiovascularSystems，Inc.的董事。劳勒先生在耶鲁大学获得公共和私人管理硕士学位，在新罕布什尔大学获得文学学士学位。
Augustine Lawlor will join the Company’s board of directors upon the completion of this offering. Mr. Lawlor has served as Chief Operating Officer of Leap Therapeutics, Inc., an oncology company, since January 2016 and has been a Managing Director of HealthCare Ventures since 2000. From 1997 to 2000 he served as Chief Operating Officer of LeukoSite, Inc., a biotechnology company acquired by Millennium Pharmaceuticals Inc. in 1999. Prior to joining LeukoSite, Mr. Lawlor was Chief Financial Officer and Vice President of Corporate Development for Alpha-Beta Technologies, Inc., a company that specializes in electronics design, development, manufacturing and system obsolescence issues. He has held similar positions at both BioSurface Technologies Corporation, a company that provides products for biofilm investigations, and Armstrong Pharmaceuticals, a division of Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company. Mr. Lawlor was previously a management consultant with KPMG. He is currently Chairman of the Board of Catalyst Biosciences, Inc. and a director of Cardiovascular Systems, Inc., biopharmaceutical companies which are listed on Nasdaq, Mr. Lawlor received his Master’s degree in Public and Private Management from Yale University and a BA degree from the University of New Hampshire. - 本次发行完成后，Augustine Lawlor将加入公司董事会。劳勒先生自2016年1月起担任肿瘤公司LeapTherapeutics，Inc.的首席运营官，并自2000年起担任梦百合Ventures的董事总经理。从1997年到2000年，他曾担任Leukosite公司（生物技术公司，于1999年被Millennium Pharmaceuticals公司收购）的首席运营官。在加入Leukosite之前，Lawlor先生是Alpha-Beta Technologies，Inc.（一家专门从事电子产品设计、开发、制造和系统过时问题的公司）企业发展的首席财务官和Vice President。他曾在Biosurface Technologies Corporation（一家为生物膜调查提供产品的公司）和Armstrong Pharmaceuticals（一家专业制药公司AmphastarPharmaceuticals，Inc.的子公司）担任类似职务。Lawlor先生此前是毕马威会计师事务所（KPMG）的管理顾问。他目前是在纳斯达克上市的生物制药公司CatalystBiosciences，Inc.的董事会主席和CardiovascularSystems，Inc.的董事。劳勒先生在耶鲁大学获得公共和私人管理硕士学位，在新罕布什尔大学获得文学学士学位。
- Augustine Lawlor will join the Company’s board of directors upon the completion of this offering. Mr. Lawlor has served as Chief Operating Officer of Leap Therapeutics, Inc., an oncology company, since January 2016 and has been a Managing Director of HealthCare Ventures since 2000. From 1997 to 2000 he served as Chief Operating Officer of LeukoSite, Inc., a biotechnology company acquired by Millennium Pharmaceuticals Inc. in 1999. Prior to joining LeukoSite, Mr. Lawlor was Chief Financial Officer and Vice President of Corporate Development for Alpha-Beta Technologies, Inc., a company that specializes in electronics design, development, manufacturing and system obsolescence issues. He has held similar positions at both BioSurface Technologies Corporation, a company that provides products for biofilm investigations, and Armstrong Pharmaceuticals, a division of Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company. Mr. Lawlor was previously a management consultant with KPMG. He is currently Chairman of the Board of Catalyst Biosciences, Inc. and a director of Cardiovascular Systems, Inc., biopharmaceutical companies which are listed on Nasdaq, Mr. Lawlor received his Master’s degree in Public and Private Management from Yale University and a BA degree from the University of New Hampshire.
高管简历
中英对照 | 中文 | 英文- Eli Hazum
Eli Hazum自2012年起担任代理首席执行官，自2018年4月起担任首席技术官，自2019年12月起担任公司董事。从2011年到2019年11月，他担任我们的首席执行官。他自1995年起担任Medica Venture Partners的合伙人和CSO。在加入Medica之前，Hazum教授在葛兰素公司（Glaxo Inc.）工作了五年，担任受体研究和代谢疾病部门的负责人，并担任全球骨质疏松症新技术识别公司委员会的成员。Hazum先生在魏茨曼科学研究所（Weizmann Institute of Science）获得激素生物化学领域的博士学位，在特拉维夫大学（Tel Aviv University）获得化学学士学位和硕士学位，并在英国汉伯赛德大学（Humberside University）获得执行工商管理硕士学位。本次发行完成后，Hazum先生将把60%的时间用于公司。
Eli Hazum has served as Chief Executive Officer since October 2021. He has been a partner and Chief Security Officer of Medica Venture Partners since 1995. Prior to joining Medica, Prof. Hazum spent five years at Glaxo Inc. as Head of the Department of Receptor Research and Metabolic Diseases and as a member of the Corporate Committee for New Technology Identification in osteoporosis, worldwide. Mr. Hazum received his Ph.D. degree in the field of hormone biochemistry from the izmann Institute of Science, B.Sc and M.Sc degrees in Chemistry from Tel Aviv University and an executive MBA degree from Humberside University in the UK.- Eli Hazum自2012年起担任代理首席执行官，自2018年4月起担任首席技术官，自2019年12月起担任公司董事。从2011年到2019年11月，他担任我们的首席执行官。他自1995年起担任Medica Venture Partners的合伙人和CSO。在加入Medica之前，Hazum教授在葛兰素公司（Glaxo Inc.）工作了五年，担任受体研究和代谢疾病部门的负责人，并担任全球骨质疏松症新技术识别公司委员会的成员。Hazum先生在魏茨曼科学研究所（Weizmann Institute of Science）获得激素生物化学领域的博士学位，在特拉维夫大学（Tel Aviv University）获得化学学士学位和硕士学位，并在英国汉伯赛德大学（Humberside University）获得执行工商管理硕士学位。本次发行完成后，Hazum先生将把60%的时间用于公司。
- Eli Hazum has served as Chief Executive Officer since October 2021. He has been a partner and Chief Security Officer of Medica Venture Partners since 1995. Prior to joining Medica, Prof. Hazum spent five years at Glaxo Inc. as Head of the Department of Receptor Research and Metabolic Diseases and as a member of the Corporate Committee for New Technology Identification in osteoporosis, worldwide. Mr. Hazum received his Ph.D. degree in the field of hormone biochemistry from the izmann Institute of Science, B.Sc and M.Sc degrees in Chemistry from Tel Aviv University and an executive MBA degree from Humberside University in the UK.
- David E. Weinstein
David E.Weinstein自2020年3月起担任我们的总裁兼首席医疗官。Weinstein博士自2019年5月起担任我们公司的顾问。自2018年10月以来，他一直担任Androbiosciences，LLC（一家专注于孤儿适应症的男性健康公司）的首席执行官，自2015年7月以来，他一直担任再生医学公司Rivertown Therapeutics，Inc.的首席执行官。他也是David Weinstein Consulting公司的总裁兼首席执行官。Weinstein博士担任Intekrin Therapeutics的首席科学与首席医疗官。Inc.从2011年到2015年5月被Coherus Biosciences Inc.收购。他于2013年至2016年为其提供咨询的纳斯达克股票代码:CHRS。他从2001年9月到2011年7月是Gliamed，Inc.的创始人和首席科学官，从2002年到2009年担任首席执行官。Weinstein博士拥有纽约大学（New York University）神经科学的医学博士学位以及硕士和博士学位。此次发行完成后，Weinstein博士将全职致力于PainReform。
David E. Weinstein has served as our President and Chief Medical Officer since March 2020. Dr. Weinstein served as a consultant to our company since May 2019. Since October 2018 he has served as CEO of AndroBiosciences, LLC, a men’s health company focused on orphan indications, and since July 2015 he has served as CEO of RiverTown Therapeutics, Inc., a regenerative medicine company. He is also the President and CEO of David Weinstein Consulting, Inc. Dr. Weinstein served as Chief Scientific and Chief Medical Officer to InteKrin Therapeutics. Inc. from 2011 until May 2015 when it was acquired by Coherus BioSciences Inc. NASDAQ:CHRS for whom he consulted from 2013 to 2016. He was the founder of and served as Chief Science Officer of GliaMed, Inc. from September 2001 to July 2011 and as Chief Executive Officer from 2002 and 2009. Dr. Weinstein holds an MD degree and MS and PhD degrees in neuroscience from New York University. Dr. Weinstein will devote his full time efforts to PainReform upon completion of this offering.- David E.Weinstein自2020年3月起担任我们的总裁兼首席医疗官。Weinstein博士自2019年5月起担任我们公司的顾问。自2018年10月以来，他一直担任Androbiosciences，LLC（一家专注于孤儿适应症的男性健康公司）的首席执行官，自2015年7月以来，他一直担任再生医学公司Rivertown Therapeutics，Inc.的首席执行官。他也是David Weinstein Consulting公司的总裁兼首席执行官。Weinstein博士担任Intekrin Therapeutics的首席科学与首席医疗官。Inc.从2011年到2015年5月被Coherus Biosciences Inc.收购。他于2013年至2016年为其提供咨询的纳斯达克股票代码:CHRS。他从2001年9月到2011年7月是Gliamed，Inc.的创始人和首席科学官，从2002年到2009年担任首席执行官。Weinstein博士拥有纽约大学（New York University）神经科学的医学博士学位以及硕士和博士学位。此次发行完成后，Weinstein博士将全职致力于PainReform。
- David E. Weinstein has served as our President and Chief Medical Officer since March 2020. Dr. Weinstein served as a consultant to our company since May 2019. Since October 2018 he has served as CEO of AndroBiosciences, LLC, a men’s health company focused on orphan indications, and since July 2015 he has served as CEO of RiverTown Therapeutics, Inc., a regenerative medicine company. He is also the President and CEO of David Weinstein Consulting, Inc. Dr. Weinstein served as Chief Scientific and Chief Medical Officer to InteKrin Therapeutics. Inc. from 2011 until May 2015 when it was acquired by Coherus BioSciences Inc. NASDAQ:CHRS for whom he consulted from 2013 to 2016. He was the founder of and served as Chief Science Officer of GliaMed, Inc. from September 2001 to July 2011 and as Chief Executive Officer from 2002 and 2009. Dr. Weinstein holds an MD degree and MS and PhD degrees in neuroscience from New York University. Dr. Weinstein will devote his full time efforts to PainReform upon completion of this offering.
- Ehud Geller
Ehud Geller自2008年11月以来一直担任我们的董事会主席，自2020年1月以来担任我们的代理首席财务官。1995年以来，他一直担任Medica Venture Partners公司的普通合伙人。1979年至1985年，Geller博士担任Teva Pharmaceutical Industries NYSE:TEVA的制药部门总裁和Teva Group的执行副总裁。在Teva，他领导收购Ikapharm Ltd.。他从1985年到1990年担任InterPharm Laboratories，Ltd.总裁和首席执行官。在这些年里，他还担任以色列制药制造商协会（Israeli Pharmaceutical Manufacturers Association）的负责人和特拉维夫证券交易所（TASE）的董事会成员。Geller博士拥有理学学士学位。化学工程学位，Columbia University/Drexel Institute工商管理硕士学位和费城Drexel Institute制药/化学工程博士学位。1995年以来，他一直担任Medica Venture Partners公司的普通合伙人。
Ehud Geller has served as the Chairman of Board of Directors since 2007. Since 1995, Dr. Geller has served as the General Partner of Medica Venture Partners. Beten 1979 and 1985, Dr. Geller was President of the Pharmaceutical Division of Teva Pharmaceutical Indtries Ltd. (NYSE:TEVA) and Executive VP of the Teva Group. At Teva, he led the acquisition of Ikapharm Ltd. He served as the President and Chief Executive Officer of Interpharm Laboratories, Ltd. from 1985 to 1990. During these years he also served as head of the Israeli Pharmaceutical Manufacturers Association and as a Board Member on the Tel Aviv Stock Exchange. Dr. Geller has a B.Sc. degree in Chemical Engineering, an MBA degree from Columbia University/Drexel Institute and a Ph.D. degree in Pharmaceutical/Chemical Engineering from Drexel Institute, Philadelphia. Since 1995, he has been the General Partner of Medica Venture Partners. Mr. Geller was selected to serve on the board of directors as Chairman due to his significant experience leading and growing companies in the pharmaceutical indtry and his significant leadership experience. His experience leading the Company's management and the depth of his knowledge of biness enable him to provide valuable leadership on complex biness matters that face on an ongoing basis. Dr. Geller will devote approximately 50% of his time to the Company, as an executive Chairman, upon completion of this offering as he also is currently employed by Medica Venture Partners.- Ehud Geller自2008年11月以来一直担任我们的董事会主席，自2020年1月以来担任我们的代理首席财务官。1995年以来，他一直担任Medica Venture Partners公司的普通合伙人。1979年至1985年，Geller博士担任Teva Pharmaceutical Industries NYSE:TEVA的制药部门总裁和Teva Group的执行副总裁。在Teva，他领导收购Ikapharm Ltd.。他从1985年到1990年担任InterPharm Laboratories，Ltd.总裁和首席执行官。在这些年里，他还担任以色列制药制造商协会（Israeli Pharmaceutical Manufacturers Association）的负责人和特拉维夫证券交易所（TASE）的董事会成员。Geller博士拥有理学学士学位。化学工程学位，Columbia University/Drexel Institute工商管理硕士学位和费城Drexel Institute制药/化学工程博士学位。1995年以来，他一直担任Medica Venture Partners公司的普通合伙人。
- Ehud Geller has served as the Chairman of Board of Directors since 2007. Since 1995, Dr. Geller has served as the General Partner of Medica Venture Partners. Beten 1979 and 1985, Dr. Geller was President of the Pharmaceutical Division of Teva Pharmaceutical Indtries Ltd. (NYSE:TEVA) and Executive VP of the Teva Group. At Teva, he led the acquisition of Ikapharm Ltd. He served as the President and Chief Executive Officer of Interpharm Laboratories, Ltd. from 1985 to 1990. During these years he also served as head of the Israeli Pharmaceutical Manufacturers Association and as a Board Member on the Tel Aviv Stock Exchange. Dr. Geller has a B.Sc. degree in Chemical Engineering, an MBA degree from Columbia University/Drexel Institute and a Ph.D. degree in Pharmaceutical/Chemical Engineering from Drexel Institute, Philadelphia. Since 1995, he has been the General Partner of Medica Venture Partners. Mr. Geller was selected to serve on the board of directors as Chairman due to his significant experience leading and growing companies in the pharmaceutical indtry and his significant leadership experience. His experience leading the Company's management and the depth of his knowledge of biness enable him to provide valuable leadership on complex biness matters that face on an ongoing basis. Dr. Geller will devote approximately 50% of his time to the Company, as an executive Chairman, upon completion of this offering as he also is currently employed by Medica Venture Partners.
- Sigal Aviel
Sigal Aviel 自2013年3月起担任MediWound Ltd.首席研发官。从2010年到2013年3月，Aviel博士担任Biokine Therapeutics Ltd.的监管和临床事务副总裁，Biokine Therapeutics Ltd.是一家专注于癌症患者药物研发的以色列私营公司。从2005年到2010年，Aviel博士担任Protalix Biotherapeutics, Inc.的高级研究总监，Protalix Biotherapeutics, Inc.是一家专注于重组治疗性蛋白质开发和制造的以色列上市公司。Aviel博士拥有以色列特拉维夫大学生物学学士学位、以色列特拉维夫大学和伊利诺伊州芝加哥西北大学的Kellogg-Recanati行政工商管理硕士学位，以及杜克大学医学中心的免疫学和微生物学博士学位。
Sigal Aviel has served as Mediwound Ltd. Chief Research and Development Officer since March 2013. From 2010 to March 2013 Dr. Aviel served as Vice President of Regulation and Clinical Affairs at Biokine Therapeutics Ltd., a private Israeli company focused on research and development of drugs for cancer patients. From 2005 to 2010 Dr. Aviel served as Senior Director of Research at Protalix Biotherapeutics, Inc., a public Israeli company focused on the development and manufacturing of recombinant therapeutic proteins. Dr. Aviel holds a B.Sc. in Biology from Tel Aviv University, Israel, a Kellogg-Recanati Executive M.B.A. from Tel Aviv University, Israel and Northwestern University, Chicago, Illinois, and a Ph.D. in Immunology and Microbiology from Duke University Medical Center.- Sigal Aviel 自2013年3月起担任MediWound Ltd.首席研发官。从2010年到2013年3月，Aviel博士担任Biokine Therapeutics Ltd.的监管和临床事务副总裁，Biokine Therapeutics Ltd.是一家专注于癌症患者药物研发的以色列私营公司。从2005年到2010年，Aviel博士担任Protalix Biotherapeutics, Inc.的高级研究总监，Protalix Biotherapeutics, Inc.是一家专注于重组治疗性蛋白质开发和制造的以色列上市公司。Aviel博士拥有以色列特拉维夫大学生物学学士学位、以色列特拉维夫大学和伊利诺伊州芝加哥西北大学的Kellogg-Recanati行政工商管理硕士学位，以及杜克大学医学中心的免疫学和微生物学博士学位。
- Sigal Aviel has served as Mediwound Ltd. Chief Research and Development Officer since March 2013. From 2010 to March 2013 Dr. Aviel served as Vice President of Regulation and Clinical Affairs at Biokine Therapeutics Ltd., a private Israeli company focused on research and development of drugs for cancer patients. From 2005 to 2010 Dr. Aviel served as Senior Director of Research at Protalix Biotherapeutics, Inc., a public Israeli company focused on the development and manufacturing of recombinant therapeutic proteins. Dr. Aviel holds a B.Sc. in Biology from Tel Aviv University, Israel, a Kellogg-Recanati Executive M.B.A. from Tel Aviv University, Israel and Northwestern University, Chicago, Illinois, and a Ph.D. in Immunology and Microbiology from Duke University Medical Center.